Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Liraglutide in Children and Adolescents with Type 2 Diabetes.

Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shehadeh N, Turan S, Weghuber D, Barrett T; Ellipse Trial Investigators.

N Engl J Med. 2019 Aug 15;381(7):637-646. doi: 10.1056/NEJMoa1903822. Epub 2019 Apr 28.

PMID:
31034184
2.

Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.

Mastrandrea LD, Witten L, Carlsson Petri KC, Hale PM, Hedman HK, Riesenberg RA.

Pediatr Obes. 2019 May;14(5):e12495. doi: 10.1111/ijpo.12495. Epub 2019 Jan 17.

3.

Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years.

Danne T, Biester T, Kapitzke K, Jacobsen SH, Jacobsen LV, Petri KCC, Hale PM, Kordonouri O.

J Pediatr. 2017 Feb;181:146-153.e3. doi: 10.1016/j.jpeds.2016.10.076. Epub 2016 Dec 13.

4.

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study.

Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L.

Int J Obes (Lond). 2015 Jan;39(1):187. doi: 10.1038/ijo.2014.88. Epub 2014 Oct 14. No abstract available.

PMID:
25311036
5.

Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

Klein DJ, Battelino T, Chatterjee DJ, Jacobsen LV, Hale PM, Arslanian S; NN2211-1800 Study Group.

Diabetes Technol Ther. 2014 Oct;16(10):679-87. doi: 10.1089/dia.2013.0366. Epub 2014 Jul 18.

6.

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.

Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L; NN8022-1923 Investigators.

Int J Obes (Lond). 2013 Nov;37(11):1443-51. doi: 10.1038/ijo.2013.120. Epub 2013 Jul 1. Erratum in: Int J Obes (Lond). 2013 Nov;37(11):1514. Int J Obes (Lond). 2015 Jan;39(1):187.

PMID:
23812094
7.

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.

Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A; LEAD-3 Study Group.

Diabetes Obes Metab. 2010 Jul;12(7):604-12. doi: 10.1111/j.1463-1326.2010.01196.x.

8.

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L; LEAD-4 Study Investigators.

Diabetes Care. 2009 Jul;32(7):1224-30. doi: 10.2337/dc08-2124. Epub 2009 Mar 16. Erratum in: Diabetes Care. 2010 Mar;33(3):692.

9.

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group.

Lancet. 2009 Feb 7;373(9662):473-81. doi: 10.1016/S0140-6736(08)61246-5. Epub 2008 Sep 24.

PMID:
18819705
10.

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM; Repaglinide Versus Nateglinide Comparison Study Group.

Diabetes Care. 2004 Jun;27(6):1265-70.

PMID:
15161773
11.

Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

Raskin P, McGill J, Saad MF, Cappleman JM, Kaye W, Khutoryansky N, Hale PM; Repaglinide/Rosiglitazone Study Group.

Diabet Med. 2004 Apr;21(4):329-35.

PMID:
15049934
12.

Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone.

Jovanovic L, Hassman DR, Gooch B, Jain R, Greco S, Khutoryansky N, Hale PM.

Diabetes Res Clin Pract. 2004 Feb;63(2):127-34.

PMID:
14739053
13.

Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM; Repaglinide vs. Nateglinide Metformin Combination Study Group.

Diabetes Care. 2003 Jul;26(7):2063-8. Erratum in: Diabetes Care. 2003 Sep;26(9):2708.

PMID:
12832314
14.

Assessment of growth and immunologic function in HIV-infected and exposed children.

Lipman TH, Deatrick JA, Treston CS, Lischner HW, Logan J, Hassey K, Hale PM, Singer-Granick C.

J Assoc Nurses AIDS Care. 2002 May-Jun;13(3):37-45.

PMID:
12064020
15.

Assessment of growth by primary health care providers.

Lipman TH, Hench K, Logan JD, DiFazio DA, Hale PM, Singer-Granick C.

J Pediatr Health Care. 2000 Jul-Aug;14(4):166-71.

PMID:
10900413
16.

Risk factors for cardiovascular disease in children with Type I diabetes.

Lipman TH, Hayman LL, Fabian CV, DiFazio DA, Hale PM, Goldsmith BM, Piascik PC.

Nurs Res. 2000 May-Jun;49(3):160-6.

PMID:
10882321
17.

Factors predicting cerebral edema in young children with diabetic ketoacidosis and new onset type I diabetes.

Hale PM, Rezvani I, Braunstein AW, Lipman TH, Martinez N, Garibaldi L.

Acta Paediatr. 1997 Jun;86(6):626-31.

PMID:
9202799
18.

Improvement of cortical morphology in infantile hydrocephalic animals after ventriculoperitoneal shunt placement.

Hale PM, McAllister JP 2nd, Katz SD, Wright LC, Lovely TJ, Miller DW, Wolfson BJ, Salotto AG, Shroff DV.

Neurosurgery. 1992 Dec;31(6):1085-96; discussion 1096.

PMID:
1470319
19.

Diagnosis and treatment of thyroid disease in infants.

Postellon DC, Hale PM.

Compr Ther. 1991 Jul;17(7):57-61. Review. No abstract available.

PMID:
1742971
20.

Testosterone infusion reduces nocturnal luteinizing hormone pulse frequency in pubertal boys.

Foster CM, Hassing JM, Mendes TM, Hale PM, Padmanabhan V, Hopwood NJ, Beitins IZ, Marshall JC, Kelch RP.

J Clin Endocrinol Metab. 1989 Dec;69(6):1213-20.

PMID:
2685008
21.

Tactical considerations for HIS strategy--Part II.

Hale PM.

Comput Healthc. 1989 Nov;10(11):44, 47, 49.

PMID:
10304093
22.

Nocturnal serum growth hormone concentration is not augmented by short-term testosterone infusion in pubertal boys.

Foster CM, Hopwood NJ, Hassing JM, Hale PM, Mendes T, Kelch RP, Beitins IZ.

Pediatr Res. 1989 Oct;26(4):320-4.

PMID:
2797945
23.

Tactical considerations for HIS strategy--Part I.

Hale PM.

Comput Healthc. 1989 Oct;10(10):39-40. No abstract available.

PMID:
10295453
24.

T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restriction.

Hale PM, Cease KB, Houghten RA, Ouyang C, Putney S, Javaherian K, Margalit H, Cornette JL, Spouge JL, DeLisi C, et al.

Int Immunol. 1989;1(4):409-15.

PMID:
2484961
25.

Effects of human growth hormone on insulin-stimulated glucose metabolism in 3T3-F442A adipocytes.

Foster CM, Hale PM, Jing HW, Schwartz J.

Endocrinology. 1988 Aug;123(2):1082-8.

PMID:
3293980
26.

The single-vendor path to the future.

Hale PM.

Healthc Comput Commun. 1988 Jul;5(7):58-60. No abstract available.

PMID:
10287795
27.

Increased luteinizing hormone pulse frequency during sleep in early to midpubertal boys: effects of testosterone infusion.

Hale PM, Khoury S, Foster CM, Beitins IZ, Hopwood NJ, Marshall JC, Kelch RP.

J Clin Endocrinol Metab. 1988 Apr;66(4):785-91.

PMID:
3346356
28.

State of the art: islet cell antibody tests.

Hale PM, Pasquarello TJ, Vardi P.

Diabetes Educ. 1987 Fall;13(4):381-5. No abstract available.

PMID:
3311673
29.

Monoclonal antibodies against ovalbumin.

Bjercke RJ, Hale PM, Mercer WD, McGuire WL.

Biochem Biophys Res Commun. 1981 Mar 31;99(2):550-6. No abstract available.

PMID:
7236283

Supplemental Content

Support Center